MedTrace Logo

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

NCT02559154 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-05-04

No results posted yet for this study

Summary

To investigate the efficacy of a modified bortezomib based combination therapy for patients with multiple myeloma.

Conditions

Interventions

DRUG

Bortezomib

DRUG

Dexamethasone

DRUG

Doxorubicin

DRUG

Cyclophosphamide

DRUG

Mitoxsnteone

DRUG

Thalidomide

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Guohua Liu, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2018-10-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559154 on ClinicalTrials.gov